SCHEMBL4429982

SCHEMBL4429982

CCCC(NC(=O)c1cc2cc(OCCOC)ccc2o1)Oc1ccc(C(N)=O)cc1O

nearest known ligand 0.52

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 14/20 0.52
TAS1R1 Q7RTX1 14/20 0.52
HDAC3 O15379 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
CHEK2 O96017 1/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4429988 0.84 TAS1R3 (0.56) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL447539 0.84 TAS1R3 (0.56) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL6419803 0.73 TAS1R3 (0.50) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL447777 0.72 TAS1R3 (0.47) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL447540 0.70 TAS1R3 (0.60) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL445060 0.70 TAS1R3 (0.53) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL706250 0.69 TAS1R3 (1.00) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL6414543 0.69 LMNA (0.62) TAS1R3TAS1R1LMNAALDH1A1
SCHEMBL701393 0.69 TAS1R3 (1.00) TAS1R3TAS1R1HDAC3HDAC1HDAC2
SCHEMBL4247496 0.68 TAS1R3 (0.57) TAS1R3TAS1R1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099442-A1 METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY PHARMACYCLICS, INC. (US) 2009-09-16 EP disclosed
WO-2008082856-A1 METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY PHARMACYCLICS, INC. (US) 2008-07-10 WO disclosed